Amid wider economic uncertainty, some analysts have said that businesses are at a "no-hire, no fire" standstill.

In the latest close session, Novo Nordisk (NVO) was down 1.59% at $52.05. The stock trailed the S&P 500, which registered a daily gain of 0.23%. On the other hand, the Dow registered a gain of 0.34%, ...

Somehow, it’s becoming even harder to get a GLP-1.

Novo Nordisk (($NVO)) announced an update on their ongoing clinical study. In a recent update, Novo Nordisk announced a new clinical study titled ...

Sure, Eli Lilly’s Tirzepatide-based drugs have caught up significantly to Novo Nordisk’s semaglutide-based ones. As a result, ...

A boardroom shake-up at Novo Nordisk has handed unprecedented power to its top shareholder, the Novo Nordisk Foundation, ...

Get the latest on Novo Nordisk's Alzheimer's trial, stock outlook, and market risks. See what investors need to know before ...

Novo Nordisk A/S found a new leader for its investor relations department in an equity analyst who has recommended buying ...

Boardroom drama at Wegovy-maker Novo Nordisk has laid bare the company's biggest challenge: how to better tap into America's ...